Daratumumab in presumed multirefractory DAT-negative autoimmune hemolytic anemia after treatment of high-grade endometrial carcinoma
Clinical Hematology International: Case Reports · 20.10.2026 · 1 (4)
DOI: 10.46989/001c.172187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Hematology International: Case Reports, online erschienen am 20.10.2026. Verfasst von Paritosh Garg und 2 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Autoimmune hemolytic anemia (AIHA) that remains active despite corticosteroids, rituximab, and conventional immunosuppressants remains a major therapeutic challenge. We report a 69-year-old woman with high-grade endometrioid adenocarcinoma of the endometrium (FIGO grade 3, pT1aN0, pMMR) treated with surgery, adjuvant chemoradiotherapy, and vaginal brachytherapy, who subsequently developed severe presumed DAT-negative autoimmune hemolytic anemia. Exact calendar dates have been removed to preserve patient confidentiality; the first relevant diagnostic clinical event is designated as Day 1 and subsequent events are reported on a relative timeline. The diagnosis was supported by anemia with reticulocytosis, very low haptoglobin, mildly elevated lactate dehydrogenase, erythroid hyperplasia on bone marrow examination, negative stool occult blood, and exclusion of paraproteinemia, while direct/indirect antiglobulin testing and monospecific Coombs testing remained negative. She was considered steroid-dependent/refractory because hemoglobin stability could not be sustained with corticosteroids and the anemia persisted despite four doses of rituximab, cyclosporine, and mycophenolate mofetil. Daratumumab was then introduced as salvage therapy, and she completed four 1800-mg subcutaneous doses; the fourth dose was administered on Day 288. Before daratumumab, hemoglobin had fluctuated despite prior therapies, reaching a nadir of 5.9 g/dL on Day 244. On follow-up after daratumumab, hemoglobin improved to 10.4 g/dL by Day 304, with no post-daratumumab red-cell transfusion requirement documented in the available records. No immediate administration-related adverse reaction was documented. This case adds to the limited adult literature describing anti-CD38 therapy as a possible salvage approach in selected patients with multirefractory AIHA, including seronegative disease, while underscoring the need for careful diagnostic caution, infectious surveillance, transfusion-planning awareness, and prospective evaluation.
Zitieren
APA
Garg, P., Trehan, M., & Bhargava, R. (2026). Daratumumab in presumed multirefractory DAT-negative autoimmune hemolytic anemia after treatment of high-grade endometrial carcinoma. Clinical Hematology International: Case Reports, 1(4). https://doi.org/10.46989/001c.172187
Vancouver
Garg P, Trehan M, Bhargava R. Daratumumab in presumed multirefractory DAT-negative autoimmune hemolytic anemia after treatment of high-grade endometrial carcinoma. Clinical Hematology International: Case Reports. 2026;1(4). doi:10.46989/001c.172187
BibTeX
@article{Garg2026,
author = {Garg, Paritosh and Trehan, Mehak and Bhargava, Rahul},
title = {Daratumumab in presumed multirefractory DAT-negative autoimmune hemolytic anemia after treatment of high-grade endometrial carcinoma},
journal = {Clinical Hematology International: Case Reports},
year = {2026},
volume = {1},
number = {4},
doi = {10.46989/001c.172187}
}
EUVIMED